These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21050352)

  • 1. Osteoporosis in patients with prostate cancer on long-term androgen deprivation therapy: an increasing but under-recognised problem.
    Langley R; Price P; Pollock P; Abel PD
    BJU Int; 2010 Sep; 106(5):726-7; author reply 727. PubMed ID: 21050352
    [No Abstract]   [Full Text] [Related]  

  • 2. Osteoporosis in patients with prostate cancer on long-term androgen deprivation therapy: an increasing, but under-recognized problem.
    Brown JE; Sherriff JM; James ND
    BJU Int; 2010 Apr; 105(8):1042-3. PubMed ID: 20201833
    [No Abstract]   [Full Text] [Related]  

  • 3. Researchers probe consequences of androgen deprivation for prostate cancer.
    Friedrich MJ
    JAMA; 2006 Nov; 296(19):2305-6. PubMed ID: 17105787
    [No Abstract]   [Full Text] [Related]  

  • 4. Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer.
    Taxel P; Dowsett R; Richter L; Fall P; Klepinger A; Albertsen P
    BJU Int; 2010 Nov; 106(10):1473-6. PubMed ID: 20456336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long term androgen deprivation therapy in prostate cancer.
    Ockrim JL; Abel PD
    BMJ; 2008 Sep; 337():a1361. PubMed ID: 18809586
    [No Abstract]   [Full Text] [Related]  

  • 6. Patient quality of life safeguarding: the primary aim in nonmetastatic prostate cancer patients.
    Cai T; Bartoletti R
    J Clin Oncol; 2007 Aug; 25(22):3385; author reply 3385-6. PubMed ID: 17664492
    [No Abstract]   [Full Text] [Related]  

  • 7. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
    Ishizaka K; Machida T; Kobayashi S; Kanbe N; Kitahara S; Yoshida K
    Int J Urol; 2007 Dec; 14(12):1071-5. PubMed ID: 18036042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis.
    Lassemillante AC; Doi SA; Hooper JD; Prins JB; Wright OR
    Endocrine; 2014 Apr; 45(3):370-81. PubMed ID: 24174178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen deprivation therapy for prostate cancer: new concepts and concerns.
    Smith MR
    Curr Opin Endocrinol Diabetes Obes; 2007 Jun; 14(3):247-54. PubMed ID: 17940447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer.
    Smith MR
    Drugs Aging; 2003; 20(3):175-83. PubMed ID: 12578398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Diethylstilbesterol revisited: androgen deprivation, osteoporosis an prostate cancer.
    Pitts WR
    J Urol; 2002 Jul; 168(1):201; author reply 201. PubMed ID: 12050534
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of treatment-related osteoporosis in men with prostate cancer.
    Smith MR
    Cancer Treat Rev; 2003 Jun; 29(3):211-8. PubMed ID: 12787715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen deprivation therapy for prostate cancer.
    Bahnson R
    J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
    [No Abstract]   [Full Text] [Related]  

  • 14. Uncovering the metabolic complications of androgen deprivation therapy in patients with prostate cancer--where do we take it next?
    Pinthus JH
    J Urol; 2015 Jun; 193(6):1882-3. PubMed ID: 25794833
    [No Abstract]   [Full Text] [Related]  

  • 15. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
    Dhanapal V; Reeves DJ
    J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
    Kudlacek S; Puntus T
    Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging cardiometabolic complications of androgen deprivation therapy.
    Choong K; Basaria S
    Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer.
    Smith MR
    Cancer Metastasis Rev; 2002; 21(2):159-66. PubMed ID: 12465755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
    Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
    J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical guide to the management of osteoporosis in men with prostate cancer receiving androgen-deprivation therapy.
    Bruder JM
    Curr Urol Rep; 2005 May; 6(3):157-8. PubMed ID: 15869718
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.